SOURCE: Stellar Biotechnologies, Inc.

Stellar Biotechnologies, Inc.

May 15, 2015 08:30 ET

Stellar Biotechnologies' Immunology 2015 Poster Available Online

PORT HUENEME, CA--(Marketwired - May 15, 2015) - Stellar Biotechnologies, Inc. ("Stellar" or the "Company") (OTCQB: SBOTF) (TSX VENTURE: KLH) today announced that the Company's poster presentation at this week's IMMUNOLOGY 2015 conference, the Annual Meeting of the American Association of Immunologists (AAI), has been posted to the Company's website. http://tinyurl.com/n5hq43w

The poster titled "Measuring the Properties of Different Forms of Keyhole Limpet Hemocyanin (KLH) Reveals Important Differences," represents results from research studies conducted by Stellar on the immunogenicity of different forms and preparations of Keyhole Limpet Hemocyanin (KLH), and relates to the Company's work in developing methods to identify the appropriate functional properties of KLH for use in immunotherapy and immunodiagnostic applications. The results showed significant differences in the efficiency of various types of KLH to elicit KLH-specific and antigen-specific adaptive immune responses.

The poster was authored by Stellar Biotechnologies' scientists Shuguang Bi, Ph.D., Laura Milbrandt, and Catherine Brisson, Ph.D. who attended IMMUNOLOGY 2015 (May 8-12, New Orleans, LA) and represented the Company's products and sustainable KLH manufacturing in an exhibit booth.

Link to Stellar's IMMUNOLOGY 2015 Poster: http://tinyurl.com/n5hq43w

About Immunology 2015
Immunology 2015, the Annual Meeting of The American Association of Immunologists (AAI), (www.immunology2015.org) brings together the world leaders in immunology to present their research in lectures and major symposia.

Stellar Biotechnologies, Inc. (OTCQB: SBOTF) (TSX VENTURE: KLH) is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, Alzheimer's, and inflammatory diseases) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.

Visit www.stellarbiotech.com and the Stellar KLH knowledge base www.klhsite.org.

Forward Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include, but may not be limited to: general economic and business conditions; technology changes; competition; changes in strategy or development plans; governmental regulations and the ability or failure to comply with governmental regulations; the timing of anticipated results; and other factors referenced in the Company's filings with securities regulators. For a discussion of further risks and uncertainties related to the Company's business, please refer to the Company's public company reports filed with the TSX Venture Exchange and the U.S. Securities and Exchange Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such statements. This press release does not constitute an offer or solicitation of an offer for sale of any securities in any jurisdiction, including the United States. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the information contained in this press release.

Contact Information

  • Stellar Biotechnologies Company Contact:
    Mark A. McPartland
    Vice President of Corporate Development and Communications
    Phone: +1 (805) 488-2800 ext. 103
    Email Contact
    www.stellarbiotech.com